SK16993A3 - Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one - Google Patents

Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one Download PDF

Info

Publication number
SK16993A3
SK16993A3 SK169-93A SK16993A SK16993A3 SK 16993 A3 SK16993 A3 SK 16993A3 SK 16993 A SK16993 A SK 16993A SK 16993 A3 SK16993 A3 SK 16993A3
Authority
SK
Slovakia
Prior art keywords
methyl
acid
tetrahydro
imidazole
mixture
Prior art date
Application number
SK169-93A
Other languages
Slovak (sk)
Other versions
SK278786B6 (en
Inventor
Clotet Juan Huguet
Ges Jose Maria Caldero
Original Assignee
Vita Invest Sa
Sint Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vita Invest Sa, Sint Quimica Sa filed Critical Vita Invest Sa
Publication of SK16993A3 publication Critical patent/SK16993A3/en
Publication of SK278786B6 publication Critical patent/SK278786B6/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

Vynález sn týka spúoobu výroby 1,2,3,9-tetrahydro-9-The invention relates to a process for the production of 1,2,3,9-tetrahydro-9-

co je syntetická zlúčenina, ktorá selektívne antayonizujo vecento ry a vykazuje zaujímavé vlastnosti .9 ako an.liete t i ká v chemoterapii, ako aj pri liečbe bolestí hlavy, schizofrénie, úzkostných stavov, obezity a mánie.is a synthetic compound that selectively antayonizes the subject matter and exhibits interesting properties .9 as those in chemotherapy, as well as in the treatment of headache, schizophrenia, anxiety, obesity and mania.

Pote rajč í stav technikyThe prior art

V patentu rb ,>4ΐ·4.Ο je opísané výroba 1,2,3,9-tetrahy 'h·..)-9-,ti e t.y 1.-3- [( b-ioe ty 1- I.H- imidnzol-l-yl) nie ty l] -4dknrbnzol-i-onu reakciou karoazolonu vzorca 111In the patent rb, > 4ΐ · 4.Ο, the production of 1,2,3,9-tetrahydro-9-, thiomethyl-3- [(b-thio-1 H- imidazol-1-yl) non-phenyl] -4-benzimidazol-1-one by reaction of the caroazolone of formula 111

(III)(III)

kde Y predsta vu je aie tyl é n s kup i.nu éteho halogénme tyl skupinu, s 2-me tyl i midazolom.wherein Y is a tylene with a halogeno group, 2-methyl midazol.

V patentu ES ///1)1 je opísaná výroba 1,2,3,9-tetrabydro-9-met yl-3~ fý 2-+5 tyl--III-irnidnzo.L-1-y I.) nie tyl] - 45.1— karbazol -4-onu oxid ár. i o u korbozo lu obecného vzorca IVIn the EC patent (1) 1, the preparation of 1,2,3,9-tetrabydro-9-methyl-3-phenylethyl-3-yl-III-nitridin-1-yl-I-1 is described. tyl] - 45,1-carbazol-4-one ox. in the case of corbozol of the general formula IV

V patentu ES /393/ o p í s .;·» n ŕ v ý r o ba 1,2,3,9-tetrahydro-9- ne tyl-3 - [(2—nie- tyl -19-i. n i.dazol-1-yl) m e tyl] -4 fi-In patent ES (393), 1,2,3,9-tetrahydro-9-yl-3 - [(2-methyl-19-nitro) -19-nitro] is described. azazol-1-yl) methyl] -4-

kcie H·, a/.alebo R-, predstavuj0 o tom vodíka.or H or R-, represent 0 about that hydrogen.

V patentu ES 290993/ je opísaná výroba 1,2,3,9-tetrahy d r o - 9 - m e ty 1 - 3 - [(c - m e t y 1 -1 H - i m i d o z o 1 -1 -y 1) m e ty 1J - 4 Hkorbazol-4-onu cyklizáct ou fenylhydrazínového derivátuIn the EC patent 290993 / the production of 1,2,3,9-tetrahydro-9-methyl-3 - [(c-methyl-1H-imidozo-1-yl) methyl 1J-4 is described. Deep corazol-4-one by cyclization of the phenylhydrazine derivative

V patentu ES 2O0'.)93ó je opísaná výroba 1,2,3,9-tetrah y d r o - 9 -1 n e t y 1 - 3 - - n i e t y 1 -111 - .i ί i i d · z o 1 -1 - y 1): 11 e t y l] - 41 í k.orb -.zol-4- Snu c y k 1 izáciou anilínového derivátu obecného vzorca VilIn the EC patent 2030-193, the production of 1,2,3,9-tetrahydro-9-1-methyl-3-methyl-1-hydroxy-1-yl-1-yl is described: 11 Ethyl] -41 ketyl-4-iso-4- Snula by cyclization of an aniline derivative of the general formula

(Víl) kde X. predstavu je atóm vodíka alebo halogénu.(VII) wherein X. the notion is hydrogen or halogen.

Podstata vynálezuSUMMARY OF THE INVENTION

Predmetom vynálezu je spúsob výroby 1,2,3,9-te trati y d r o - 9 - me ty 1 - 3 - {k 2 -nie ty 1 -1! I - i m i d --j z ol --1 - y 1) me tyl j - 4 (Ίkarbazol-4-ónu obecného vzorca IIt is an object of the present invention to provide a process for the production of 1,2,3,9-th-methyl-9-methyl-3- (k-2-yl) -yl-1-carboxylic acid. I - i m i d - j z ol - 1 - y l) methyl j - 4 (Carbazol-4-one of formula I)

ktorého podstata spočíva v tom, že sa 2-[(2-metyl-lH-im.idazol-l-yl)metylj-4-il-metylindol-2-yl)kyselina maslováwhich comprises 2 - [(2-methyl-1H-imidazol-1-yl) methyl] -4-ylmethylindol-2-yl) butyric acid

(U) cyklizuje za podmienok 'Priedel-Crai' tsove j acylačnej reakcie prostredníctvom aktivácie karboxylovej skupiny pomocou kyslej(U) cyclizes under conditions of 'Priedel-Crai' ts acylation reaction through activation of the carboxyl group by acidic

I k atalýzy , v prostredí vhodného rozpúš C n dl o , načo sa oožodo verný prodiiikt obvyklým spSsob o m izoluje.Even in an environment of suitable dissolution, the rational product is isolated in a conventional manner.

A k t i v é c i. a k' a ľ· b o x y 1 o v e j 3 k u p i n y s o j: r e v á d z a p r· e v á d z a ním karboxylovej kyseliny na halogenid kyse.l iny alebo zmesný anhydrid a k y s e 1. i. n o u t r i C1 u ó r. · 3 c t o v o u j 11 e t ŕ n s u 1 f r ) n o v o u a 1 o b o t r i f 1 u o r metŕnsulfonovou, prednostne na zmesný anhydrid s ryseli.nou trifl uóroct )vou.A k t i v c i. and wherein the carboxylic acid is mixed with the carboxylic acid halide or mixed anhydride and the carboxylic acid anhydride is 1. n o u t r i C1 u ó r. 3-methanesulfonic acid, preferably to the mixed anhydride with the characteristic trifluronic acid.

Ak.) kyslého katalyzátoru sa rn^že poučiť anorganickej k y s e 1 i ny, a k > k y s e 1 i ny c h 1 o r o v o d í k. o vej, rečnej alebo Lewisovej kyseliny, ako je chlorid zinočriatý alebo chlorid hlinitý í r o v e j a .1 e b o f o o f o fluorid borit.ý,If the acid catalyst can be used, inorganic crystals may be used, and the acid catalysts may be used. oic, or Lewis acid, such as zinc chloride or aluminum chloride; and.

Prednostne sa p i užíva seliny fosforečnej.Phosphorus selins are preferably used.

a prevédza v aprotiekom organickom rozpúšťadle, o f orm. d ichl irine tan. dichloretáand converting in an aprotic organic solvent, form. d ichl irine tan. dichloretá

Reakcia 5) íi k o j e c hl o r tetrahydrof urán alebo acetoni tri.l, prednostne v acetoni trií u.Reaction 5) is a mixture of tetrahydrofuran or acetone tri, preferably in acetonitrile.

Cyklizáeia sa účelne prevádza pri tapolote v rozmedzí od -60 do -»-!?03C, prednostne pri ·.'> 3C.Cyklizáeia preferably takes the tapolote in the range of -60 to - »- !? 0 3 C, preferably at ·. '> 3 C.

Po dokončení reakcie sa požadovaný produkt konvenčným spôsob oni izoluje n prekrystal izu je z organického rozpúšťadla, prednostne me tanolu. Získa sa chemicky čistý 1,2,3,9-tetrahydro-9-met,yl-3- [( z-metyl-ld-i midazol-l-yl) m e tyl} -4K- ť knrbazol-4-on.Upon completion of the reaction, the desired product is conventionally isolated and recrystallized from an organic solvent, preferably methanol. Chemically pure 1,2,3,9-tetrahydro-9-methyl-3 - [(2-methyl-1H-imidazol-1-yl) methyl} -4K-tertbazol-4-one is obtained.

Zlúčenina obecného vzorca ii sa m3že vyrobiť reakciou 2ľie t y lén - i - (- k a r boxy-1-me ty 1 indol -z-.vl) ma sl ovej kyseliny v z o r c a V L .1. i .The compound of formula (ii) can be prepared by the reaction of 2'-thiene-i - (- k-box-1-methyl-indol-2-yl) -malic acid in zinc and in L.1. i.

s 2-metylimidazolom. Reakcia sa účelne prevádza pri teplote v rozmedzí od 100 do 2ΌΌ °C, prednostne pri 150 °C.with 2-methylimidazole. The reaction is conveniently carried out at a temperature in the range of from 100 to 2 ° C, preferably at 150 ° C.

Reakcia sa prevádza vo vysokovrúcom rozpúšťadle, ako je toluén, xylén alebo hrombenzén alebo ich zmesi, .‘'lebo bez rozpúšťadla. Prednostne sa pracuje bez rozpúšťadla.The reaction is carried out in a high boiling solvent such as toluene, xylene or thiobenzene or mixtures thereof, or without a solvent. Preferably, the process is carried out without solvent.

Po dokončení reakcie sa oožadovaný produkt konvenčnými prostriedkWizoluje a prekry 1 tniizuje z organického rozpúšťadla,ako metanolu, toluénu, diinetoxyotánu alebo metoxyetanolu, prednostne dimetoxyetánu.Upon completion of the reaction, the desired product is isolated by conventional means and recrystallized from an organic solvent such as methanol, toluene, di-ethoxyotane or methoxyethanol, preferably dimethoxyethane.

Dikarboxylová kyselina vzorcu VIII sa' získa hydrolýzou 2tne ty lén-P - (3-e toxy karbonyl-1-metyl indol-2-yl) maslové j k y s e 1 i ny v z o r c a i XThe dicarboxylic acid of formula VIII is obtained by hydrolyzing 2-thiene-β- (3-ethoxycarbonyl-1-methyl-indol-2-yl) butyric acid with zinc and X

ľúto zlúčeninu je potom možno vyrobiť reakciou etyl 1,2-d.i;n e t y 1 i n d o 1 - 3 - k a r h o xy 1 ó t u v z )r c a X (X)The lithium compound can then be produced by reacting ethyl 1,2-dihydroxy-1-3-cyclohexyl-1-ol and X (X).

(ktorý sa získa spôsobom opísaným v John E) ftyan, Michael E. Newman, J. Org. Ohern. 54, <A-bróminetylakrylovou kyselinou vzorca XI(obtained by the method of John E) phthane, Michael E. Newman, J. Org. Ohern. 54, N-bromoethylacrylic acid of formula XI

Mne or, Kov·/i n 4735, 1939) s (XI)Me or, Metal · / i n 4735, 1939) s (XI)

Brbr

OOOHOOOH

Vynález je bližšie objasnený v následujúcich príkladoch prevádzania. Tieto príklady majú výhradne ilustratívny charakter n rozsah vynálezu v žiadnom ohíade neomedzujú.The invention is illustrated by the following examples. These examples are illustrative only and do not limit the scope of the invention in any respect.

P r í klady pre v á d z ani a vynálezuExamples of the invention

-me ty lén-4 - ( 3 - e t o xyk m r bony 1.-1 - o ·-· ty 1 í nd .Ί -2-yl) masl o v k / s ·? L i. n a roztoku lítnej soli, ktorá bola vyrobená z 4,34 g (20 mmól) etyl 1,2-dioetylindol-3-korboxy.).ŕtu, vo 150 ml tetrahydrof uránu, udržiavonúh :> pri -90 JC, sa v pri e hehe 10 s pridá roztok 4,99 y (30 m.'nol) e^-brommetylakryiovej kyseliny vo 20 ml to trahydrof ur ' nu. ľ;;- plota by nemala prestúpili -50 ‘'C. Po d vochhod i nov on n i. o n o ni u pri -9 0 0C sa roztok naleje do zmesi obsahujúcej 400 >·· ír.du, 15 ml koncentrovane j kyseliny chlorovodíkovej o 2 1.) ml. e ty L oco t.átu. Po rozdelení aa fáza oddelí n vodná vrstva sa extrahuje etylacet.átom (2 x 200 •ni). Spojené organické extrakty sa vysušia síranom horečnatým a odparia. Výsledná pevná látka sa prekrystalizuje z toluénu a potom z metanolu. Získa sa 3,0 g (50 &) analyticky čistej titulnej zlúčeniny, vo forme bielej pevnej látky.-methylene-4- (3-ethoxycyclones-1-o-o-butylamino-2-yl) butter / sec. L i. on a solution of the lithium salt, which was made from 4.34 g (20 mmol) of ethyl 1,2-dioethylindole-3-carboxylate, in 150 ml of tetrahydrofuran, kept at > A solution of 4.99 g (30 mmol) of n-bromomethylacrylic acid in 20 ml of tetrahydrofuran was added over a period of 10 s. ; ;; - the fence should not exceed -50 ° C. After all, he is new. add it at the -9 0 0 C, the solution was poured into a mixture of 400> ·· ír.du, 15 ml of concentrated hydrochloric acid j 2 1) ml. e ty L oco t.át. After partitioning and phase separation, the aqueous layer was extracted with ethyl acetate (2 x 200 mL). The combined organic extracts were dried (MgSO 4) and evaporated. The resulting solid was recrystallized from toluene and then from methanol. 3.0 g (50%) of analytically pure title compound are obtained as a white solid.

Teplota tope .>enia: 138 a Ž 140 °n ^1-4045(0001^): l,4ó (t, J - 7,1, 34, -0^-01^), 2,52 - 2,71Melting point: 138 DEG-140 DEG .alpha.: 1-4045 (0001): 1.4 (t, J = 7.1, 34, -0.6% -01), 2.52-2.71

(m, 211, (m, 211 -Cil, -Cil. -0 = C -0 = C ), 3,35» ), 3.35 » N-CiJ-3) ,N-CiJ- 3 ), 4,41 4.41 (q, (Q, J = 7,1 J = 7.1 111, -0=0 111, -0 = 0 4), 4), c,37 C, 37 (d , J - (d, J - i ŕ'; 11 rí ÍL 1 trf i '; 11 Oct 1 trf 5ý), 5Y) 8,1' 8,1 ' . ) — c., zO . ) - c., ZO

J - 1,5, III, 7,25 (m, 21i,J - 1.5, III, 7.25 (m, 21i,

P r x k 1 a d 2P r x k 1 and d 2

2--ne ty lén-4 - ( 3-karbox.y-l- ae tyl indol-2-yl) maslová kyselina2-Non-thien-4- (3-carboxy-1-methyl-indol-2-yl) butyric acid

K. suspenzii 5 ,7 g (18,9 .nmol) zlúčeniny z príkladu 1 v 15 ml metanolu a 15 ml vody sa pridá 19 g hydroxidu draselného a vzniknutá zmes sa 30 minút varí pod spätným chladičom. Potom sa zmes naleje do zmesi 200 g l'adu a 200 ml vody a okyslí 30 ml koncentrovane j kyseliny chlorovodíkovej. Produkt sa odfiltruje a suspenduje vo zpO ml toluénu. Potom sa 100 ml toluénu zo zmesi oddestiluje a po ochladení na 20 °0 a ďalšou filtráciou sa získa 4,5 g (07 Ί) analyticky čistej titulnej zlúčeniny vo forme bielej pevnej látky.To a suspension of 5.7 g (18.9 µmol) of the compound of Example 1 in 15 ml of methanol and 15 ml of water was added 19 g of potassium hydroxide, and the resulting mixture was heated under reflux for 30 minutes. The mixture is then poured into a mixture of 200 g of ice and 200 ml of water and acidified with 30 ml of concentrated hydrochloric acid. The product is filtered off and suspended in 10 ml of toluene. Thereafter, 100 mL of toluene was distilled off from the mixture and after cooling to 20 ° 0 and further filtration, 4.5 g (07 Ί) of the analytically pure title compound was obtained as a white solid.

Teplota topenia: 194 a z 195 °C 1H-NMPS(CDC1 p: 2,40 - 2,00 (m, 211, indol-C^-CH -). 3,20 3,00 (m, 211, indol-Clh-ClI;.~) , 3,77 (s, 3H, N-CH^), 5,59 (d, -C=C-H), 5,07 (d, J = 1,5, III, -0=0-11), 7,10 aromatický), 7,45 -- 7,o4 (m, 1H, aromatický),Melting point: 194-195 ° C 1 H-NMPS (CDCl 3: 2.40-2.00 (m, 2H, indole-C ^-CHCH)) 3.20 3.00 (m, 2H, indole-) CLH-CII,. ~), 3.77 (s, 3H, N-CH), 5.59 (d, -C? CH), 5.07 (d, J = 1.5, III, -0 = 0-11), 7.10 aromatic), 7.45-7.4 (m, 1H, aromatic),

7,96 - 8,05 (’ľi, l.ii, mromn tie ký ).7.96 - 8.05 (´i, liiii, mighty ones).

P r· í k 1 n d 3Example 1

- / ( P-mety 1-1 H- im idazol-l-yl] -4- (1-mety.1 i nehol-2-y 1) maslovú kyselina.- (P-Methyl-1H-imidazol-1-yl) -4- (1-methyl-indol-2-yl) -butyric acid.

Zmes 2,73 g (lOm.'nol) zlúčeniny z príkladu 2 a 2,46 g (30 -íimol) 2-;:ietyli::)idazolu sa p minúty zahrieva na lóO °C. Po ochladení na teplotu miestnosti sa zmes rozpustí v chloreformu, nanesie na chroj'iatogrní ický stĺpec oxidu kremičitého a eluuje zmesou metylénchlorid/metanol, 7θ :A mixture of 2.73 g (10 mmol) of the compound of Example 2 and 2.46 g (30 mmol) of 2-methyl-idazole was heated at 10 ° C for a minute. After cooling to room temperature, the mixture is dissolved in chloroform, applied to a silica column and eluted with methylene chloride / methanol, 7θ:

3 0. i a k. s ? i z 1 s an*-·) y lieky čis3 0. i and k. with ? iz 1 s an * - ·) y medicines no k 2 tej k 2 the > n > n 21 g oži t 21 g oži t (71 4) (71 4) titulnej zlúčeniny vo vne j látky. of the title compound in the external substance. forme a k. a v e j k. a v e j j p j p Teplo ta topení Heat the heater a: 1 a: 1 ;> ;> ζ·\ · ζ \ until ). 9 ). 9 0 p 0 p LH-6 49^(0001^) L H-6 49 ^ (0001 ^) : 1, : 1, 0 0 ) ) - - 2,00 2.00 (, ( ' -ml, indol-CIĽ-O!-^-) , -ml, indole-CIĽ-O! ^) 2,27 2.27 (s, 3Π, C-C.l-J (s, 3Π, C-C.1-J > 0, > 0, 0 0 y y - - 2,90 2.90 ( Ή , (Ή, 4 i, indol-OH·- a -HOĽ 4 i, indole-OH · - and -HOL COOlí) , COOlí), 3,.-3 (s, 3H, M 3.3-3 (s, 3H, M n; J .J n; J .J ) ) j j 3, 3 o .> - o.> - 3 , <- 3, <- ‘y (m, 21), imidnzol-CH., ‘Y (m, 21), imidazole-CH., -), -) ó,lp (s, .14!, indol δ, lp (s, !14), indole - - Π) Π) > > υ,79 υ, 79 i-d, i-a, J - i, ô, 1H, iínidazol J-i, δ, 1H, imidazole -H), H) 6,60 - 7,10 (m 6.60 - 7.10 (m , 30) , 30) ) ) v č v č e 11 ι- e 11 ι- p r i. at. 7,06 (d, J - 1,6, 1H, 7.06 (d, J = 1.6, 1H, iiuidazol-íl) , 7 imidazol-1), 7 , 30 , 30 - - 7 7 /1 ) *’ / 1 ) * ’ Ο (.1., . (.1., 21! 21! , arómá tie ký) , aromas)

1,2 , 3,9-t e t r a-hy dr o-y-'.iin tyl-3- [(2 — me tyl-lH-imidrzol-ly 1) m e t y lj - 4 H - k n r b a z o 1 - 4 - ó n1,2,3,9-tetrahydro-y-ylamino-3 - [(2-methyl-1H-imidrzol-1-yl) methyl] -4H-pyrimidin-4-one

K suspenzii 311 mg (1 ? ml acetonitrilu sa pridá 2 fosforečnej. Reakčná zmes nej 35341)- (2,5 mmol) anhy mul) zlúčeniny 2 príkladu 3 v 10 c u.L (0,P6 kyseliny sa ochladí na 0 JC a prikvapá sa k dridu trifluoroctovej kyseliny. Po 15To a suspension of 311 mg of (1? Ml of acetonitrile was added 2 phosphoric acid. The mixture there 35341) - (2.5 mmol) of scrim anhydrides) of 2 of Example 3 in 10 uL c (0, P6 acid was cooled to 0 C and dropwise, J to the trifluoroacetic acid dride

I.I.

tT

... 9 _ minútach sa zar.es naleje do zmesi 50 y íadu a 50 ml nasýteného roztoku hyHroycnuhl i. č i tanú sodného a vzniknutá1 · zmes sa extrahuje >';ty.l.ón e hl >ridom (3 x 13 m±). opojené organické extrakt;/ sa vysni i a síranom horečnatým a odparia. Pevný zv.yšok sa prekry í tal i žuje z metanolu a tak sa získa lóO mg (552·) titulnej zlúčeniny vo forme analyticky čistej bielej pevnej látky.The mixture was poured into a mixture of 50 ml of ice and 50 ml of saturated aqueous solution for 9 minutes. No carbonate solution and the resultant one was extracted ·>'; ty.l.ón much hl> hydride (3 x 13 m ±). the combined organic extract is dried over magnesium sulphate and evaporated. The solid residue was recrystallized from methanol to give 10 mg (552%) of the title compound as an analytically pure white solid.

Teplota topenia: 227 až’2'28,5 3CMelting point: 227 C 3 až'2'28,5

H-NmRé'kGDCl^ H ^ NmRé'kGDCl ): 1, ): 1, 70 70 “ 2 , “2, 03 (m, 03 (m, 1H, 11-0(2)), 1 H, 11-0 (2)), 2,45 2.45 (s (with , 3H, , 3H, CH, ) , CH,), H-G(3)), 3,72 H-G (3)), 3.72 (s, (with, 3 íl 3 íl , M-C , M-C H·/ 4 H · / 4 M-Gll2), 4,73M Gly-2), 4.73 (d d, (d d, J J = 4,1 = 4.1 5, 1H, 5, 1H, aromatický), aromatic), 7,20 7.20 - - 7,40 7.40 (rn, 3 H (rn, 3H 8,<·.<) - 3,30 ( 8, <·. <) - 3.30 ( m, .1.1 m, .1.1 J J aróma aroma tieký. Tekla.

1:1, H-C(2) ) ,2,13 - 4,30 (m,. 2,75 - 3,1? (m, 3Π, H-C(l) a 10 (dcl, J = 8,15, 1H,1: 1, HC (2)), 2.13-4.30 (m, 2.75-3.1? (M, 3Π, HC (1) and 10 (dcl, J = 8.15, 1H) .

N-Crl^) , ó, 85 - 7,05 (m, 21i, imidazol-H a aromatický) ,N-Cr (4), δ, 85-7.05 (m, 21i, imidazole-H and aromatic),

Ρ Λ T E N T .) V É ÍH R O K ΪΡ Λ T E N T.) OVERHEAD Ϊ

L. JpSsob výroby 1,2 , 3 , 9-t.ô trahydro-9-me tyl-3- [(2:,-ie tyl-ltl-imidazol-l-yl )me ty tj -4H-karbazol-4-ónu vzorca 1 v y i III i dL. Jp Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3 - [(2, 1-yl-1H-imidazol-1-yl) methyl] -4H-carbazole-4 -one of formula 1 or III id

a izol-l-yl) nie vzorca iiand iso-1-yl) not of formula ii

t, ý m, ž e sa 2 - [_(2 nie tyl-1Hlová kyselina — Λ— í 1 -Ίΐοΐ·,ν1 i ndo'lcharacterized in that 2 - [(2-notyl-1H-1-hylic acid) - 1 - (1 -) -, 1-indole

c jkli žuje za podmienok Priedel^Graftsovej acylačne j reakcie prostredníctvom aktívácie karboxylovej skupiny pomocou kyslej katalýzy, v prostredí vhodného rozpúšťadla, na čo sa požadovaný produkt obvyklým spúsobom izoluje.It follows the conditions of the Priedel Grafts acylation reaction by activation of the carboxyl group by acid catalysis, in a suitable solvent environment, for which the desired product is isolated in the usual manner.

Claims (4)

i.i. Spúsob podťa nároku 1,vyznačujúci sa t ý in, že sa zlúčenina vzorca íl aktivuje vytvorením zmesného anhydridu, prednostne zmesného anhydrido s k y.; r? 1 i no u t r i +'1 u o x· o c t. o v o u.10. The method of claim 1, wherein the compound of formula III is activated by forming a mixed anhydride, preferably a mixed anhydride with kyl; r? 1 i no u t r i + 1 u o x · o c t. o v o u. 3. cpúsob pod L* ó nároku 1 alebo 2, vyznačujúci s a t ý m, že sa cyklizácia prevádza vo vhodnom rozpúšťadle .'·· za prítomnosti kyslého katalyzátoru.Process according to Claim 1 or 2, characterized in that the cyclization is carried out in a suitable solvent in the presence of an acid catalyst. 4. Spôsob počin niektorého z nárokov 1 až J, vyznáč u j ú c i s a t ý m, že sa ako reakčného prostredia4. A process as claimed in claim 1, wherein the reaction medium is a p o u g i. j e 3 pr o t i. c k č h p o u g i. j e 3 pr o t i. c k č h o o r p a n .i. c k é h o r o z j > ú š ťi a č 1 o o r p a n .i. c k h o r o z i s> a 1 a, prednostne and, preferably acetóni tri.lu. acetones tri.lu. b. Jp^sob počin b. Np nároku 3, v y s n a č u of claim 3 j ú c i sa it is t ý m, že sa ako k is that as k yslóho katalyzátoru pouŽ use of a high catalyst i je kyseliny i is an acid fosforečnej. phosphoric acid. - - Spôsob počin Way of action n i e k t o r · é h o z n á r o k o v 1 n i e k t o r o h o n o n o v 1 n ž ·!, v y z na- n ž · !, v y z na- č u j ú r; i sa č u j úr; i sa t ý m, že sa c y k1 i z á c i a in that the c y k1 i z i a pne v ád z a pri teplote at any temperature v r o z.ifioč 7. í. oč - ÓO v r o z.ifioč 7. í. - Oh do t 50 °C, prednostne up to 50 ° C, preferably pri 0 JC.at 0 J C.
SK169-93A 1992-03-13 1993-03-08 -1h-imidazole-1-yl)methyl|-4h-carbazol-4-one SK278786B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09200552A ES2043535B1 (en) 1992-03-13 1992-03-13 PROCEDURE FOR OBTAINING 1,2,3,9-TETRAHYDRO-9-METHYL-3- (2-METHYL-1H-IMIDAZOL-1-IL) METHYL * -4H-CARBAZOL-4-ONA.

Publications (2)

Publication Number Publication Date
SK16993A3 true SK16993A3 (en) 1993-11-10
SK278786B6 SK278786B6 (en) 1998-02-04

Family

ID=8276385

Family Applications (1)

Application Number Title Priority Date Filing Date
SK169-93A SK278786B6 (en) 1992-03-13 1993-03-08 -1h-imidazole-1-yl)methyl|-4h-carbazol-4-one

Country Status (15)

Country Link
KR (1) KR100277414B1 (en)
AR (1) AR248019A1 (en)
AT (1) AT402730B (en)
CZ (1) CZ281753B6 (en)
EG (1) EG20262A (en)
ES (1) ES2043535B1 (en)
FI (1) FI105098B (en)
GR (1) GR930100094A (en)
HU (1) HU210775B (en)
IS (1) IS1783B (en)
NO (1) NO300973B1 (en)
PL (1) PL170751B1 (en)
PT (1) PT101216B (en)
RU (1) RU2109741C1 (en)
SK (1) SK278786B6 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100368895B1 (en) * 2000-03-30 2003-01-24 하나제약 주식회사 A process for preparing 1,2,3,9-tetrahydro-9-methyl-3- [(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502508A1 (en) * 1984-01-25 1985-08-14 Glaxo Group Ltd., London HETEROCYCLIC COMPOUNDS
GB8518742D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518741D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8617994D0 (en) * 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
NO300973B1 (en) 1997-08-25
HUT64537A (en) 1994-01-28
SK278786B6 (en) 1998-02-04
CZ39693A3 (en) 1994-01-19
ES2043535A1 (en) 1993-12-16
GR930100094A (en) 1993-11-30
KR100277414B1 (en) 2001-01-15
KR930019665A (en) 1993-10-18
FI931104A (en) 1993-09-14
PL298037A1 (en) 1993-12-27
NO930887D0 (en) 1993-03-11
PT101216B (en) 1999-10-29
EG20262A (en) 1998-05-31
IS1783B (en) 2001-10-22
ES2043535B1 (en) 1994-08-01
FI931104A0 (en) 1993-03-12
PT101216A (en) 1994-03-31
IS3985A (en) 1993-09-14
FI105098B (en) 2000-06-15
CZ281753B6 (en) 1997-01-15
HU210775B (en) 1995-07-28
ATA48793A (en) 1996-12-15
HU9300718D0 (en) 1993-05-28
PL170751B1 (en) 1997-01-31
RU2109741C1 (en) 1998-04-27
AT402730B (en) 1997-08-25
NO930887L (en) 1993-09-14
AR248019A1 (en) 1995-05-31

Similar Documents

Publication Publication Date Title
Xie et al. Efficient synthesis of pyrrolo [1, 2-a] quinoxalines catalyzed by a Brønsted acid through cleavage of C–C bonds
US5252584A (en) Hydroxyquinolone derivatives
CA1094084A (en) Halo-substituted 1-loweralkyl-5-aroylpyrrole-2-acetic acid compounds
EP0397060A2 (en) Maleinimide derivatives and their use as medicines
JPH02142791A (en) Pyrrolocarbazole derivatives, and their preparation and use as medicines
AU729386B2 (en) 1,2-diarylindole as cox-2 inhibitors
CA1246563A (en) 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl- 1h-indoles useful as analgesics
CA1332836C (en) 3-oxadiazole and 3-carboxylic acid .beta.-carboline derivatives, their production and their use as drugs
JP2002508368A (en) Dihydrobenzofuran
CA1136139A (en) Polycyclic indole derivatives
Molina et al. Fused carbazoles by tandem Aza Wittig/electrocyclic ring closure. Preparation of 6H-pyrido [4, 3-b] carbazole, 11H-pyrido [4, 3-a] carbazole and 11H-pyrido [3, 4-a] carbazole derivatives
JPS60158176A (en) Substituted imidazole, manufacture and medicine
SK16993A3 (en) Process for preparing 1,2,3,9-tetrahydro-9-methyl-3- -[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazole-4-one
Nagakura et al. Syntheses and antiinflammatory actions of 4, 5, 6, 7-tetrahydroindazole-5-carboxylic acids
US5973165A (en) Process for preparing 2-oxindole
PL88788B1 (en) Triazolo-isoindole and triazolo-isoquinoline derivatives and their manufacture and uses[gb1477302a]
PL92627B1 (en)
AU7961398A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
JPS59118748A (en) Substituted azabicycloalkane, manufacture and medicine
JPS60130567A (en) 3-substituted-2-phenylindole derivative
Lawton et al. Regioselectivity in the photochemical ring contraction of 4-diazopyrazolidine-3, 5-diones to give aza-β-lactams
US3886154A (en) Method for the preparation of phthalazino (2,3-B) phthalazine-5(14H), 12(7H)-dione
HU192416B (en) Process for preparing indole derivatives and pharmaceutical compositions containing sucg compounds
Strakova et al. 1-(2-Quinoxalyl)-, 1-[3, 5-Di (trifluoromethyl) phenyl]-, 1-(2-Carboxyphenyl)-, and 1-Ethoxycarbonyl-4-oxo-4, 5, 6, 7-tetrahydroindazoles
JPH01265074A (en) Novel 7-acylindole derivative

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110308